Shuayb Elkhalifa, Jack Devey, Abdulrahaman Al-Asali, Haggar Elbashir, Maja Bulatović Ćalasan, Rick G Pleijhuis, Ingrid Terreehorst, Fulvio Salvo, Irfan Shafiq, Said Isse, Mohamed Abuzakouk, Mohamed Medhat Gaber, Rehan Bhana
Penicillin allergy is recorded in roughly one in ten hospital patients, yet fewer than one in ten of those records reflects a real, clinically significant allergy. The mismatch matters: patients with a penicillin label receive more second-line and broader-spectrum antibiotics, with measurable downstream costs in infection, surgical site morbidity, length of stay, and antimicrobial resistance. Specialist-led skin testing and graded oral challenge remain the diagnostic standard, but the global allergy workforce cannot test the population that needs testing. Validated decision rules such as PEN-FAST, structured non-allergist pathways, and direct oral challenge in low-risk patients have closed part of that gap, but uptake is still limited by inconsistent free-text documentation, variable clinician confidence, and weak integration with electronic health records. This review summarises how computational methods are being added to that pathway. Supervised machine-learning models can mine electronic health records to identify candidates for review. Natural language processing can recover the timing, character, and severity of a reaction from clinic letters that the structured allergy field omitted. Predictive models that combine clinical, laboratory, and immunological inputs are starting to outperform rule-based scores on beta-lactam risk. Decision-support systems are moving past simple drug-name matching toward context-aware alerts. Image classifiers and large language models are opening a route to rapid, photograph-and-history triage. We discuss what is needed for any of this to be safe in routine care: representative training data, transparent model behaviour, regulatory alignment, and prospective evaluation against the outcomes the antimicrobial stewardship community already measures.